Jeremie Calais, Director, Clinical Research Program at UCLA Nuclear Medicine and Theranostics, shared a post on LinkedIn:
“The ANDROMEDA trial is now open at UCLA!
Randomized Phase 2 investigator-initiated trial (NCT07150715) led by Amar Kishan, supported by Novartis, building on the LUNAR trial results (NCT05496959):
Arm 1: Neo-Adj Lutetium-177-PSMA x2 + SBRT
versus
Arm 2: Neo-Adj Actinium-225-PSMA x1 + SBRT
~100 patients with oligorecurrent prostate cancer
Goal: delay progression and ADT initiation
Let’s see if Actinium-225 can be even more effective at targeting microscopic disease?”
More posts featuring Jeremie Calais.